Ken Griffin Moon Lake Immunotherapeutics Call Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2025 May 15, 2025	SELL	$36.75 - $54.34 $88,200 - $130,416	-2,400 Reduced 20.87%	9,100 $355,000
Q4 2024 Feb 14, 2025	SELL	$45.84 - $57.91 $77,928 - $98,447	-1,700 Reduced 12.88%	11,500 $611,000
Q3 2024 Nov 14, 2024	SELL	$40.15 - $55.4 $164,615 - $227,140	-4,100 Reduced 23.7%	13,200 $665,000
Q2 2024 Aug 14, 2024	SELL	$38.43 - $48.6 $495,747 - $626,940	-12,900 Reduced 42.72%	17,300 $760,000
Q1 2024 May 15, 2024	BUY	$43.78 - $63.86 $201,388 - $293,756	4,600 Added 17.97%	30,200 $1.52 Million
Q4 2023 Feb 14, 2024	BUY	$36.35 - $63.02 $145,400 - $252,080	4,000 Added 18.52%	25,600 $1.55 Million
Q3 2023 Nov 14, 2023	BUY	$48.35 - $61.26 $1.04 Million - $1.32 Million	21,600 New	21,600 $1.23 Million

163

55.2M

481K

229K

Ticker MLTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,925,600
Market Cap $1.92B
Description
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.